Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Nathan Kline Institute for Psychiatric Research Jazz Pharmaceuticals |
---|---|
Information provided by: | Nathan Kline Institute for Psychiatric Research |
ClinicalTrials.gov Identifier: | NCT00594256 |
The present protocol proposes study of the recently approved compound sodium oxybate (Xyrem), a GABAB and a g-hydroxybutyric acid (GHB) receptor agonist, for the study of persistent symptoms of schizophrenia. Sodium oxybate is a central nervous system depressant currently approved for treatment of narcolepsy associated with cataplexy and excessive daytime sleepiness. In addition to evaluating effects on sodium oxybate on persistent symptoms and neurocognitive deficits in schizophrenia, the study will test the hypothesis that this medication may be particularly effective in combating Insomnia Related to Schizophrenia, and in normalizing symptomatic and polysomnographic manifestations of sleep-related brain dysfunction in schizophrenia.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia Insomnia Associated to Schizophrenia |
Drug: Sodium Oxybate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Open Label, Pilot Study of Adjunctive Xyrem (Sodium Oxybate) for the Treatment of Schizophrenia and Associated Sleep Disturbances |
Estimated Enrollment: | 8 |
Study Start Date: | May 2008 |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: Sodium Oxybate
Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
|
Rationale/Study Hypothesis:
Rationale for study of sodium oxybate is twofold: first, sleep dysfunction is an important and overlooked aspect of schizophrenia intrinsically linked to cognitive and functional impairments, and, second, GABAB receptors regulate dopaminergic and glutamatergic systems in vivo, suggesting that GABAB agonists may be therapeutically beneficial in schizophrenia.
We are aware of three previous trials of GHB in schizophrenia, two of which did not show any overall benefit in psychopathology. We noted multiple limitations in the controlled trials, including:
We propose an open label, proof of concept study evaluating the effect of sodium oxybate on insomnia in schizophrenia. The primary hypothesis of the study is that patients treated with sodium oxybate will show improved subjective sleep as measured by the overall Epworth Sleepiness Scale and the Pittsburgh Sleep Quality Index. Secondarily, we expect superior reduction in total psychopathology and PANSS factor scales (PANSS), polysomnographic measures, and neurocognition (MATRICS).
Design and dosage schedule:
We plan to enroll eight hospitalized patients with DSM-IV-TR schizophrenia and insomnia related to schizophrenia. The study will include: a one-week evaluation period, which will include tapering of any hypnotics, baseline diagnostic, psychopathology, neurocognitive, electrophysiological and polysomnographic measurements. Patients will then begin a four-week trial of adjunctive sodium oxybate, with a three-week taper of sodium oxybate to follow. Hypnotic/sodium oxybate taper may be extended or abbreviated, depending on clinical judgment.
Patients entering the study will be permitted to receive both typical and atypical antipsychotics. Treating psychiatrists will be encouraged to maintain fixed doses of all psychotropic medication throughout the study.
Other than haloperidol and benztropine prn (up to 10 mg/day of haloperidol), the prescription of a new psychotropic will not be permitted. After the second week of study medication, any subject requiring more than 4 doses of haloperidol in one week will be considered to have relapsed, and will be withdrawn from the study.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Joshua T Kantrowitz, MD | jkantrowitz@nki.rfmh.org | |
Contact: Daniel C Javitt, MD PhD |
United States, New York | |
Nathan Kline Insitute for Psychiatric Research | Recruiting |
Orangeburg, New York, United States, 10962 | |
Principal Investigator: Daniel C Javitt, MD | |
Sub-Investigator: Joshua T Kantrowitz, MD | |
Sub-Investigator: Leslie L Citrome, MD MPH |
Principal Investigator: | Daniel C Javitt, MD PhD | Nathan Kline Institute for Psychiatric Research |
Responsible Party: | Nathan Kline Institute ( Daniel Javitt, MD, PhD ) |
Study ID Numbers: | 07I/C36-0 |
Study First Received: | January 3, 2008 |
Last Updated: | January 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00594256 |
Health Authority: | United States: Institutional Review Board |
Schizophrenia Sleep Architecture Sodium Oxybate Insomnia Cognition |
Sleep Initiation and Maintenance Disorders Schizophrenia Mental Disorders Dyssomnias Sleep Disorders |
Psychotic Disorders Sodium Oxybate Schizophrenia and Disorders with Psychotic Features Sleep Disorders, Intrinsic |
Anesthetics, Intravenous Adjuvants, Anesthesia Anesthetics, General Therapeutic Uses Physiological Effects of Drugs |
Nervous System Diseases Central Nervous System Depressants Anesthetics Central Nervous System Agents Pharmacologic Actions |